Evidence of Sex-related Differences in Cytochrome P450 2C19 and 3A4 Mediated Metabolism of Omeprazole: Observations in an Understudied Population in South-East Anatolia in Turkey

Publisher： Bentham Science Publishers

E-ISSN： 1875-6913|11|3|247-252

ISSN： 1875-6921

Source： Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol.11, Iss.3, 2013-09, pp. : 247-252

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cytochrome P450 2C19 (CYP2C19) genotype appears to affect the efficacy of omeprazole

By  

Inpharma, Vol. 1, Iss. 1221, 2000-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

The Effect of Aging on the Relationship between the Cytochrome P450 2C19 Genotype and Omeprazole Pharmacokinetics

By Ishizawa Yukio   Yasui-Furukori Norio  

Clinical Pharmacokinetics, Vol. 44, Iss. 11, 2005-01 ,pp. : 1179-1189

Adis International

Access to resources Recommend Favorite

Interaction Profile of Armodafinil with Medications Metabolized by Cytochrome P450 Enzymes 1A2, 3A4 and 2C19 in Healthy Subjects

By Darwish Mona  

Clinical Pharmacokinetics, Vol. 47, Iss. 1, 2008-01 ,pp. : 61-74

Adis International

Access to resources Recommend Favorite

Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism

By Desta Z.   Zhao X.   Shin J-G.   Flockhart D.A.  

Clinical Pharmacokinetics, Vol. 41, Iss. 12, 2002-01 ,pp. : 913-958

Adis International

Access to resources Recommend Favorite

Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma

By Quinn David I.  

Clinical Pharmacokinetics, Vol. 48, Iss. 3, 2009-01 ,pp. : 199-209

Adis International

Access to resources Recommend Favorite